House Bill Would Eliminate COVID-19 Drug, Vaccine Cost-Sharing For Most Americans
Executive Summary
After failing to get many co-pay waivers in earlier coronavirus relief legislation, the House tries again – with an even bolder ask covering more Americans. The bill would also speed up CDC’s guidance on vaccines and ensure Medicare Part D plans cover all coronavirus treatments. But its not clear whether the Senate will get on board.
You may also be interested in...
Antibiotics Could See New Boosts From Medicare Rule, House Bill
US House looks to give BARDA more money for antibiotic development in next coronavirus relief bill, while Medicare broadens the types of antibiotics eligible for additional payments to include drugs approved under FDA's limited population antibiotic development pathway. But it's unclear whether the House funding can make it through the Senate and how meaningful the Medicare provision will be given few LPAD approvals.
Federal Official Would Monitor 'Price Gouging’ Under Latest US House Pandemic Relief Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.
'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.